Bupivacaine Hydrochloride, E · 3,135 days since initial FDA posting
Brand: BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE
FDA lists Bupivacaine Hydrochloride, E as Active Shortage (Hospira, Inc., a Pfizer Company).
Availability on file: Unavailable
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection: Active Shortage
Unavailable Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)
- Package NDC
- 0409-9042-17
Status & Timeline
- Status
- Active Shortage
- Availability
- Unavailable
- First Reported
- Feb 20, 2018
- Last Updated
- Mar 13, 2026
- Therapeutic Category
- Anesthesia
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
Nearby, Other Bupivacaine Shortage Records
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection
Fresenius Kabi USA, LLC
Injection
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection
Fresenius Kabi USA, LLC
Injection
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection
Fresenius Kabi USA, LLC
Injection
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection
Fresenius Kabi USA, LLC
Injection
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection
Fresenius Kabi USA, LLC
Injection
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection
Fresenius Kabi USA, LLC
Injection
FDA reason on file: Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay. General shortage guidance lives on the tracker hub.